Bridging Discovery and CMC with Rapid Pools

The rapid growth of complex antibody modalities—including bispecifics, multispecifics, Fc-fusions, and emerging formats—has widened the gap between discovery-stage expression systems and manufacturability. Transient expression, still widely used for screening and optimization, often fails to reveal architecture-driven liabilities such as chain imbalance, mispairing, instability, aggregation, or poor effective yield. As a result, promising molecular formats may be prematurely deprioritized based on incomplete expression data, or advanced with hidden risks that surface only during cell line development and CMC.

Asimov’s Rapid Pools platform addresses this challenge by enabling high-throughput generation of stable CHO expression pools using a new high-efficiency transposase, CHO-K1 GS host, and model-guided vector design. By providing early, CLD-relevant expression and assembly data, RapidPools allow protein engineers to directly evaluate the manufacturability of complex architectures during the design phase. This enables informed sequence, vector, and chain-balancing optimizations that can derisk differentiated formats that might otherwise be dropped, while more accurately identifying designs unlikely to scale.

Attendees will learn how integrating stable expression readouts into protein engineering workflows improves predictability, reduces late-stage risk, and expands the viable design space for next-generation antibody therapeutics.